Guido Cavaletti

Full Professor

+39 02 6448 8039
Guido Cavaletti

Curriculum Vitae


MD, Board in Neurology.

Senior consultant neurologist and head of the Neuroimmunology Center, S. Gerardo Hospital, Monza (Italy).

Head of the Experimental Neurology Unit at the School of Medicine and Surgery and former Director of the PhD program in Neuroscience, University of Milano-Bicocca, Monza.

Member of the Board of Directors of the Peripheral Nerve Society as Chair of the Toxic Neuropathy Consortium.

Vice Rector for Research at the University of Milano-Bicocca.

Coordinator of the steering committee of the international CI-PeriNoms group on the investigation of chemotherapy-induced peripheral neurotoxicity.

Author of more than 300 peer-reviewed papers (Scoups h-index = 57).



  • Preclinical and clinical assessment of chemotherapy-induced peripheral neurotoxicity
  • Preclinical and clinical assessment of diabetic neuropathy
  • Experimental autoimmune encephalomyelitis and multiple sclerosis
  • Use of mesenchimal stem cells in models of neurological diseases
  • Biological effects of synchrotron radiation



The research project is focused on the study of the pathogenesis of chemotherapy-induced peripheral neurotoxicity  (CIPN) and on its characterization in proper animal models.  It will be developed  with the Experimental Neurology Unit (ENU) and it will include mechanistic studies in vitro based on primary (neuronal, glial) and organotypic (dorsal root ganglia) cultures, as well as the implementation of in vivo mice/rat CIPN models. Behavioral, neurophysiological and pathological methods currently available at the ENU will be used in the in vivo studies.

Given the expertise available at the ENU on all the neurotoxic anticancer drugs available in clinical practice, the selection of the test drug for the studies will be performed at the moment of the project beginning, in order to design the most up-to-date experiments able to address relevant clinical issues. The test drug will be selected among platinum-based compounds, antitubulins or proteasome inhibitors, drugs used in the treatment of more than 50% of cancer patients undergoing chemotherapy.

Upon specific agreement and according to the experimental design, part of the project could be performed at the Center for Studies on Pain of the University of Maryland, Baltimore, MD



Find out more on SCOPUS



  • Johns Hopkins University, Baltimore, MD (Prof. D. Cornblath, Prof. A. Hoke, Dr. B. Slusher)
  • University of Maryland, Baltimore, MD (Prof. S. Dorsey, Dr. C. Renn)
  • Amsterdam University, Amsterdam, The Netherlands (Prof. T. Postma)
  • Maastricht University, Maastricth, The Netherland (Dr. I. Merkies)
  • Bellvitge University Hospital, Barcelona, Spain (Dr. Jordi Bruna)
  • Columbia University, New York (Dr. F. Bartolini, Dr. F. Lotti)
  • Patras University Hospital, Patras (Dr. A. Argyriou)